HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

MT-103 Micromet/MedImmune.

Abstract
Micromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia.
AuthorsEleanor J Cheadle
JournalCurrent opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 8 Issue 1 Pg. 62-8 (Feb 2006) ISSN: 1464-8431 [Print] England
PMID16506527 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Bispecific
  • blinatumomab
Topics
  • Animals
  • Antibodies, Bispecific (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
  • Clinical Trials, Phase I as Topic
  • Drug Industry
  • Humans
  • Lymphoma, B-Cell (drug therapy)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: